<![CDATA[This study aimed to analyze endocan levels as a marker of endothelial dysfunction in the control group, patients with stage I hypertension, stage II hypertension, and patients with end-stage renal disease. Endocan levels were measured with ESM-1 (endocan) kit by Enzyme-Linked Immunosorbent Assay (ELISA) method. This study used a cross-sectional method and was conducted in Dr. Wahidin Sudirohusodo Hospital, Makassar and Hasanuddin University Hospital from September to October 2017. There were 83 samples in this study, consisting of 12 samples in the control group, 22 samples of stage I hypertension, 28 samples of stage II hypertension, and 21 samples of end-stage renal disease aged 20-90 years old. This study showed significantly higher endocan levels in patients with stage II hypertension and end-stage renal disease (p< 0.05). Endocan levels were significantly higher (p<0.05) in patients with end-stage renal disease compared with the control group and patients with stage I hypertension; but not significantly higher (p > 0.05) compared to patients with stage II hypertension. Also, the median of endocan levels in patients with the end-stage renal disease was higher (309,850 ng/L) compared to patients with stage II hypertension (273,050 ng/L).]]>
Copyrights © 2020
